Eisai initiates two phase III trials with FYCOMPA (Perampanel) for epilepsy

Eisai has announced the initiation of two multicenter, global phase III clinical trials assessing FYCOMPA (perampanel) CIII in two different patient populations: patients age 2 years and above with in…
Read the full story: CenterWatch News Online